Calidi Loss Down 23 Percent in Fiscal Q2
Calidi Biotherapeutics (NYSEMKT:CLDI), a biotechnology company developing stem cell-based and enveloped virus platforms for cancer therapy, released its second quarter 2025 results on August 8, 2025. The most notable news was a net loss attributable to common stockholders of $5.7 million (GAAP), or $(1.99) per share (GAAP), slightly worse than analyst expectations of $(1.92) per share (GAAP). Despite narrowing losses compared to the prior year and continued progress in its pipeline, the period highlighted persistent funding needs and a significant reduction in available cash. The quarter showed incremental operational improvements but underscored ongoing development-stage risks typical of clinical-stage biotech firms.
Source: Analyst estimates for the quarter provided by FactSet.
Calidi Biotherapeutics is focused on developing novel cancer treatments using stem cell-based delivery systems and enveloped virus platforms. The company's strategy is to leverage allogeneic stem cells, which are donor-derived and can be used for any patient, to enhance the effectiveness of oncolytic viruses. This approach is designed to shield therapeutic viruses from immune clearance, improve their delivery to tumor sites, and trigger immune system attacks against cancer.
Source Fool.com
